Associations of alternative markers of glycemia with hemoglobin A 1c and fasting glucose

Clinical Chemistry

Volumn 58, Issue 12, 2012, Pages 1648-1655

  Juraschek, Stephen P ^a   Steffes, Michael W ^b   Selvin, Elizabeth ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; FRUCTOSAMINE; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C;

AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY DISEASE; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DIET RESTRICTION; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; SELF REPORT;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DEOXYGLUCOSE; FASTING; FEMALE; FRUCTOSAMINE; GLYCOSYLATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPERTENSION; MALE; RENAL INSUFFICIENCY, CHRONIC; SERUM ALBUMIN; SEX FACTORS;

EID: 84870321341     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.188367     Document Type: Article

References (24)

1. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan DM, Peterson CM. Tests of glycemia in diabetes. Diabetes Care 2003;26 Suppl 1:S106-8.
2. Buse JB, Freeman JLR, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-anhydroglucitol (Glyco-Mark): a short-term glycemic marker. Diabetes Technol Ther 2003;5:355-63.
3. Armbruster DA. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 1987;33:2153-63.
4. Rondeau P, Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie 2011;93:645-58.
5. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 2006;295: 1688-97.
6. Rodríguez-Segade S, Rodríguez J, Cabezas-Agricola JM, Casanueva FF, Camiña F. Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A1c). Clin Chem 2011;57:264-71.
7. Nayak AU, Holland MR, Macdonald DR, Nevill A, Singh BM. Evidence for consistency of the glycation gap in diabetes. Diabetes Care 2011;34:1712-6.
8. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989;129:687-702.
9. Jackson R, Chambless LE, Yang K, Byrne T, Watson R, Folsom A, et al. Differences between respondents and nonrespondents in a multicenter community-based study vary by gender ethnicity. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. J Clin Epidemiol 1996;49:1441-6.
10. White AD, Folsom AR, Chambless LE, Sharret AR, Yang K, Conwill D, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol 1996;49:223-33.
11. Wagenknecht L, Wasserman B, Chambless L, Coresh J, Folsom A, Mosley T, et al. Correlates of carotid plaque presence and composition as measured by MRI: the Atherosclerosis Risk in Communities Study. Circ Cardiovasc Imaging 2009;2:314-22.
12. Koskinen P, Irjala K. Stability of serum fructosamine during storage. Clin Chem 1988;34:2545-6.
13. Nathan DM, Steffes MW, Sun W, Rynders GP, Lachin JM. Determining stability of stored samples retrospectively: the validation of glycated albumin. Clin Chem 2011;57:286-90.
14. Selvin E, Rynders GP, Steffes MW. Comparison of two assays for serum 1,5-anhydroglucitol. Clin Chim Acta 2011;412:793-5.
15. Selvin E, Francis LMA, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, et al. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care 2011;34:960-7.
16. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
17. Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089-100.
18. Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med 2011;154:303-9.
19. Stettler C, Stahl M, Allemann S, Diem P, Schmidlin K, Zwahlen M, et al. Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care 2008;31:1534-5.
20. Allgrove J, Cockrill BL. Fructosamine or glycated haemoglobin as a measure of diabetic control? Arch Dis Child 1988;63:418-22.
21. Jones IR, Owens DR, Williams S, Ryder RE, Birtwell AJ, Jones MK, et al. Glycosylated serum albumin: an intermediate index of diabetic control. Diabetes Care 1983;6:501-3.
22. Howey JE, Bennet WM, Browning MC, Jung RT, Fraser CG. Clinical utility of assays of glycosylated haemoglobin and serum fructosamine compared: use of data on biological variation. Diabet Med 1989;6:793-6.
23. Narbonne H, Renacco E, Pradel V, Portugal H, Vialettes B. Can fructosamine be a surrogate for HbA(1c) in evaluating the achievement of therapeutic goals in diabetes? Diabetes Metab 2001;27:598-603.
24. Juraschek SP, Steffes MW, Miller ER 3rd, Selvin E. Alternative markers of hyperglycemia and risk of diabetes. Diabetes Care 2012;35:2265-70.